NCT03314870 (Breast-sign) is a NA clinical trial of Genetic signature in Breast Cancer, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain.

Who is sponsoring NCT03314870?

NCT03314870 is sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain.

What drugs are being tested in NCT03314870?

Interventions in NCT03314870: Genetic signature.

What condition does NCT03314870 study?

NCT03314870 studies Breast Cancer.

Is NCT03314870 still recruiting?

NCT03314870 is currently status unknown. Last updated 15 July 2019.

Last reviewed 2019-07-15 · How we verify

NCT03314870: Breast-sign

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development of a Response Signature to Neoadjuvant Chemotherapy for Breast Cancer

Status unknown NA Last updated 15 July 2019

What this trial tests

NA trial testing Genetic signature in Breast Cancer in 220 participants. Status unknown.

Timeline

7 August 2017

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	220
Start date	7 August 2017
Primary completion	31 December 2019
Estimated completion	31 December 2019
Sites	1 location across Belgium

Drugs / interventions tested

Genetic signature

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain — full company profile →

Who can join

18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Breast cancer is the most frequent cancer in women. It is often treated with neoadjuvant chemotherapy, administered before surgical resection. Unfortunately, many patients do not respond to this treatment, or only respond partially. Clinicians therefore need predictive biomarkers of treatment response. Thanks to an innovative technique, called CATS, this study aims at identifying blood and tissue biomarkers which are predictive of response to chemotherapy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives.
Varnier R, Sajous C, de Talhouet S, Smentek C, et al · · 2021 · cited 20× · PMID 34638325 · DOI 10.3390/cancers13194840
Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers.
Derouane F, Desgres M, Moroni C, Ambroise J, et al · · 2024 · cited 19× · PMID 38374113 · DOI 10.1186/s13058-024-01788-8
Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial-mesenchymal transition and tumor-infiltrating lymphocytes.
Derouane F, Ambroise J, van Marcke C, Van Bockstal M, et al · · 2025 · cited 5× · PMID 39912409 · DOI 10.1002/1878-0261.13813

Verify or expand the search:

Other trials of Genetic signature

Trials testing the same drug.

NCT04067882 — Validation of the Genetic Signature 354849 as a Prognostic Method · unknown

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Cliniques universitaires Saint-Luc- Université Catholique de Louvain trials

Trials by the same sponsor.

NCT07464938 — New Tools and Predictive Markers in the Prognosis of Hypoxic-ischemic Encephalopathy Following Cardiac Arrest · NA · recruiting
NCT07173036 — Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification Accordin · NA · not yet recruiting
NCT07245745 — Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer · NA · recruiting
NCT07588490 — Treatment of Acute Low Back Pain With Transcutaneous Electrical Neurostimulation in Emergency Departments · NA · recruiting
NCT07161219 — Implementation of New Exercise Protocols in Cardiac Rehabilitation. · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03314870 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Last refreshed: 15 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03314870.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing